Pasithea Therapeutics Shares Are Trading Higher After the Company Announced Preclinical Efficacy Data for PAS-004 From NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics 公佈了來自 NRAS 突變癌症異種移植模型的 PAS-004 的臨床前療效數據後,股價上漲
Pasithea Therapeutics Shares Are Trading Higher After the Company Announced Preclinical Efficacy Data for PAS-004 From NRAS Mutation Cancer Xenograft Models
Pasithea Therapeutics 公佈了來自 NRAS 突變癌症異種移植模型的 PAS-004 的臨床前療效數據後,股價上漲
使用瀏覽器的分享功能,分享給你的好友吧